ATS Corporation Overview
ATS Corporation is one of the world's largest independent automation solutions providers. It designs, builds, commissions and services custom and repeatable automated manufacturing, assembly, test, processing and packaging systems for multinational customers in regulated, high-reliability markets. Life sciences is its largest vertical, accounting for 51% of FY2026 adjusted revenue. It is followed by consumer products and warehouse packaging, food and beverage (including global tomato-processing leadership through CFT), energy (notably CANDU nuclear refurbishment and small-modular-reactor programs) and a shrinking, now-repositioned transportation/EV business. FY2026 adjusted revenue was C$2.97 billion. Roughly one-third of revenue is reoccurring aftermarket, spares and repeat product revenue, which partly cushions the project cycle. ATS combines a decentralized, acquisition-built portfolio with a lean operating system, the ATS Business Model (ABM). Under a new CEO, it is resetting its cost base through an 18-month Fixed Cost Transformation Program aimed at a 15% adjusted operating margin.
Company's own description (FY2026 / Q1 FY2027 disclosure)
ATS describes itself as an industry-leading automation solutions provider to many of the world's most successful companies. It says it applies its knowledge base and global capabilities across custom automation, repeat automation, automation products, and value-added solutions including pre-automation and after-sales services. These capabilities address the manufacturing automation and service needs of multinational customers. In the Q1 FY2027 boilerplate the end-markets are listed as life sciences, food and beverage, industrial and consumer, and energy. Transportation was folded into "industrial & consumer" from Q1 FY2027.
What ATS actually does — independent characterization
ATS is best understood as a portfolio of engineered-equipment and systems-integration businesses run under a common operating system and capital-allocation framework. It operates at four layers of the industrial value chain:
-
Pre-automation and engineering. Concept design, simulation, process development, digital and MES integration (Process Automation Solutions, IPCOS, IT.ACA) and front-end engineering for nuclear and SMR programs.
-
Custom integration and automation systems. Turnkey, one-off or low-volume production lines. Examples include auto-injector and wearable-device assembly for pharma (GLP-1 programs), contact-lens lines, pre-filled syringe lines, EV battery-module assembly historically, and nuclear fuel-handling and refurbishment tooling.
-
Products and equipment. Standardized or modular machines and platforms, sold repeatedly. Examples are SuperTrak linear-motor conveyance, freeze-dryers and laboratory equipment (SP Industries), radiopharmaceutical isolators and hot cells (Comecer), tube fillers and cartoners (IWK), packaging machinery (Paxiom, NCC), tomato and fruit processing lines (CFT), optical sorters (Raytec Vision), and laboratory-animal water systems (Avidity Science).
-
Services including spare parts. Aftermarket parts, retrofits, upgrades, field service, digital and consulting services across a large installed base. Management is embedding services directly into operating units to capture lifecycle revenue.
Revenue model mix
| Revenue type (FY2026) | CAD Mn | % of total |
|---|---|---|
| Revenues from construction contracts (percentage-of-completion project revenue) | 1,599.2 | 53.8 |
| Services rendered | 723.9 | 24.4 |
| Sale of goods | 647.0 | 21.8 |
| Total | 2,970.1 | 100.0 |
| Offering (FY2026) | CAD Mn | % of total |
|---|---|---|
| Custom integration and automation systems | 1,033.7 | 34.8 |
| Products and equipment | 927.1 | 31.2 |
| Services including spare parts | 1,009.3 | 34.0 |
| Total | 2,970.1 | 100.0 |
ATS discloses revenue on three overlapping bases.
By contract type (FY2026, adjusted revenue C$2,970.1M, source: Q4 FY2026 release)
By offering (FY2026)
The mix has shifted meaningfully toward products and services. Custom integration was 46.9% of revenue in FY2024 (C$1,422.3M of C$3,032.9M) and is 34.8% in FY2026, while services including spares rose from 27.3% to 34.0%. Management guides that "reoccurring revenues" will be 25%–35% of trailing-twelve-month revenue. On the Q4 FY2026 call, management said reoccurring revenue was about one-third of FY2026 revenue. ATS has no meaningful subscription or licensing revenue line. Software revenue (MES, Illuminate-type data platforms, PA digital services) is embedded in services and custom integration. In Q1 FY2027 ATS took a C$7.1M impairment on deferred development assets in its "smaller software-focused businesses."
Customer types and end-markets
Customers are predominantly large multinationals: global pharmaceutical and medical-device companies, consumer-goods and e-commerce/warehouse operators, food and beverage processors, nuclear utilities and fuel fabricators, and automotive/EV OEMs and tier-1s, although this last group is being de-emphasized. The Q4 FY2026 release highlighted several large enterprise life-sciences programs with long performance periods. ATS flags customer-concentration risk in its AIF, and the FY2025 C$171.1M settlement with a single EV customer shows how a single program can swing results.
FY2026 adjusted revenue by market: life sciences 51.2%, consumer products 18.6%, food and beverage 16.8%, energy 7.6%, transportation 5.7%. Entering FY2027, about 80% of backlog is in regulated markets (life sciences, energy, food and beverage), per the Q4 FY2026 call.
Value-chain position and economics
ATS sits between component and robot suppliers (servo, PLC, vision, robotics vendors) and end manufacturers. Its value-add is application engineering, integration risk-taking and validated-process know-how, especially for regulated GMP and nuclear environments.
The economics are structurally mid-margin:
-
FY2026 gross margin was 28.6% (calculated from IFRS revenue less cost of revenues).
-
The adjusted operating margin (adjusted earnings from operations, "AEO") was 10.6%.
-
The adjusted EBITDA margin was 13.9%.
These margins sit below proprietary-product automation peers but above pure integrators. Working-capital intensity is significant because contract assets and milestone billing create cash-flow volatility. Non-cash working capital was 22.4% of revenue at FY2025 and 12.1% at FY2026.
Strategy
Stated strategy (FY2026 annual report / MD&A and Q1 FY2027)
ATS's value-creation strategy has three pillars:
- Organic growth, outgrowing its chosen end markets through global scale, technology differentiation and the ABM.
Disciplined acquisitions: that give access to attractive end markets, products and technologies at hurdle-rate returns.
Margin expansion: through the ABM, commercial discipline, aftermarket mix and cost actions.
It is underpinned by the ATS Business Model (ABM), a lean, Danaher-style operating system covering strategy deployment, kaizen, standard work and talent.
Under Doug Wright, the framing has shifted toward a "Growth Algorithm" focused on per-share cash generation. It combines organic growth, disciplined M&A, margin expansion and better working-capital efficiency, supported by a cash return on investment (CROI) and ROIC capital-allocation framework (Q1 FY2027 release). Management has said the program "is not intended to alter" the strategic focus on services or the end markets served.
Strategic initiatives — last 24 months
| Initiative | Announced | Scope | Targets / status |
|---|---|---|---|
| Fixed Cost Transformation Program | 6 August 2026 | Multi-phase, about 18-month program to simplify the operating structure, optimize the global footprint and cut facility overhead, indirect costs and SG&A | Expected to deliver about half of the margin expansion needed to reach the 15% adjusted EFO target. Phase 1 (European Footprint Consolidation): about C$20M annual savings, about 30% of the total opportunity. Implied total program savings about C$65–70M a year (calculated from the 30% figure). Program costs not yet disclosed. |
| Transportation reorganization and repositioning | Q4 FY2026 (May 2026) | Consolidate transportation-focused divisions; sell surplus facilities; redeploy laser welding, vision and precision test capabilities to data-center, warehouse and industrial uses | C$28.3M charge in Q4 FY2026 and C$9.2M in Q1 FY2027. About C$50M of dilutive revenue exits in FY2027. Transportation no longer reported separately from Q1 FY2027. |
| Services reorganization | FY2026 | Embed services in operating units for installed-base accountability and lifecycle capture | C$9.8M (Q4 FY2026) and C$4.7M (Q1 FY2027) of redundant-asset costs. Aims to lift reoccurring revenue above the 25–35% range over time. |
| Lab-equipment go-to-market reorganization | FY2026 | Coordinated commercial approach across SP Industries, Avidity and other lab businesses | Early pipeline building (FY2026 and Q1 FY2027 MD&A). |
| Software-business portfolio review | Q1 FY2027 | Reassessment of deferred development assets in smaller software-focused businesses | C$7.1M impairment. |
| Nuclear and SMR investment | Ongoing | Reinvest part of the reorganization savings in nuclear; FEED, prototype and fuel-fabrication automation | Energy backlog up 40% year over year at FY2026. |
| Radiopharmaceuticals | Ongoing | Comecer containment plus ATS integration and lifecycle support across the radiopharma value chain | Repeat bookings in Q4 FY2026 and Q1 FY2027. |
| ERP upgrade and ICFR remediation | FY2026–FY2027 | Upgrade ERP in one international division to fix a material weakness | Implementation planned within FY2027. |
| Capital return: NCIB | December 2025 | Repurchase up to 8,225,621 shares (as announced) | 1,119,413 shares bought through August 2026 at an average of C$27.97. Management expects to stay active. |
| Restructuring program, FY2025–FY2026 | FY2025 / Q3 FY2026 | Cost-structure actions | About C$20M expected in Q3–Q4 FY2026; C$23.1M recorded in FY2026. |
Sustainability commitments
ATS frames part of its funnel around customer decarbonization: nuclear, grid storage and sustainable packaging. Specific corporate emissions targets were not found in the documents reviewed.
Management guidance and medium-term targets
| Item | Guidance / target | Source |
|---|---|---|
| Q2 FY2027 revenue | C$660M–C$700M | Q1 FY2027 release |
| FY2027 revenue | "Modest" organic growth, now contingent on stronger bookings and execution in H2 FY2027; includes about C$50M transportation exit | Q4 FY2026 and Q1 FY2027 releases |
| FY2027 adjusted EFO margin | +50 to +75 bps year over year, not linear by quarter | Q4 FY2026 release |
| Long-term adjusted EFO margin | 15% (unchanged; may be updated as progress is made) | Q4 FY2026 and Q1 FY2027 |
| Leverage | 2.0x–3.0x net debt / pro forma adjusted EBITDA throughout FY2027 | Q1 FY2027 |
| Non-cash working capital | Below 15% of annualized revenue (long-term) | Q4 FY2026 |
| Reoccurring revenue | 25%–35% of trailing-twelve-month revenue | Q1 FY2027 |
| FY2027 capex plus intangibles | C$70M–C$90M | Q1 FY2027 call |
| Q1 FY2027 restructuring | C$10M–C$15M expected; C$5.7M recorded, with the remainder shifting to Q2–Q3 | Q1 FY2027 |
| Long-term growth | Grow revenue faster than chosen end markets | Q4 FY2026 |
The Q4 FY2026 release also refers to a "multi-year free cash flow target" in forward-looking statements. The numeric target was not found in the excerpts reviewed.
Products & Services
Note: ATS does not publish a consolidated product catalog with pricing. Pricing is project-quoted. Unit prices are not publicly disclosed for any line. Brand lists below are drawn from ATS releases (including the May 2024 Paxiom announcement, which named CFT, Raytec Vision, Marco, IWK and NCC as packaging and food businesses) and acquisition disclosures. Launch and latest-version years are given only where known.
Life Sciences
| Offering / brand | Description & capabilities | Target customer | Notes |
|---|---|---|---|
| ATS Life Sciences custom automation | Turnkey automated assembly and test lines for auto-injectors, pen injectors, wearable drug-delivery devices, contact lenses, pre-filled syringes, diagnostics, inhalers and catheters. GMP-validated. | Global pharma, biotech and medtech (including GLP-1 drug-delivery producers) | Flagship of the large enterprise programs. Management expected GLP-1-related revenue to move toward a high-single-digit % of total revenue (FY2024 outlook). Activity normalized in FY2027. |
| Sortimat | Medical-device and pharmaceutical assembly automation (Germany) | Medtech and pharma OEMs | Acquired 2011 (about $62M). |
| IWK Verpackungstechnik | Tube-filling machines, cartoners and secondary packaging for pharma and cosmetics | Pharma and consumer health | Acquired about 2014. Also serves consumer markets. |
| Comecer | Radiopharmaceutical containment: isolators, hot cells, dispensing and synthesis containment, aseptic processing | Radiopharma producers, nuclear medicine, isotope producers, hospitals | Core of the radiopharmaceutical strategy. Q4 FY2026 and Q1 FY2027 bookings included radiopharma orders. |
| SP Industries (SP Scientific and related brands) | Freeze-dryers (lyophilization), laboratory evaporators, temperature-controlled equipment and lab supplies | Pharma R&D, CDMOs, academic and government labs | Exposed to constrained U.S. lab funding; a coordinated lab-equipment go-to-market reorganization is under way (FY2026 MD&A). |
| Avidity Science | Water purification and related systems for life-science research facilities | Research institutions, pharma vivariums | Acquired FY2024. |
| Automated pharmacy solutions | Automation for pharmacy dispensing and fulfillment | Pharmacies, health systems | Named in the FY2026 outlook funnel. |
Industrial & Consumer (formerly Consumer Products and Transportation)
| Offering / brand | Description & capabilities | Target customer | Notes |
|---|---|---|---|
| SuperTrak CONVEYANCE (including SuperTrak GEN3) | Intelligent linear-motor conveyance platform with independently controlled movers for high-speed flexible assembly; used inside ATS systems and sold to third-party OEMs and integrators | Consumer goods, medtech, battery and electronics manufacturers; OEM machine builders | ATS's best-known proprietary product platform. |
| Warehouse packaging automation | Automated packaging and end-of-line systems for e-commerce and fulfilment | E-commerce, retail and consumer logistics | Driver of the 80.6% Q4 FY2026 consumer-products revenue increase. |
| Paxiom Group (including product lines such as weigh-filling, bagging, wrapping, labeling, conveyors, case forming, robotic case packing and palletizing) | Primary, secondary and end-of-line packaging machines | Food and beverage, cannabis, pharma | Acquired FY2025; complements CFT, Raytec, Marco, IWK and NCC. |
| NCC Automated Systems | Packaging automation equipment | Consumer and pharma packaging | Named in the Paxiom release as an ATS packaging business. |
| Repositioned transportation capabilities | Laser welding, machine vision, high-precision test, battery module and pack assembly, e-drive and powertrain test | Automotive/EV OEMs and tier-1s; being redeployed toward data-center infrastructure and other mission-critical industrial production | Three smaller U.S. facilities closing. Two U.S. facilities and one German facility held for sale. About C$50M of dilutive revenue to be exited in FY2027. |
| High-speed assembly for consumer goods | Custom lines for personal care, household products, electronics and appliances | Consumer-goods multinationals | Historic core competence. |
Food & Beverage
| Offering / brand | Description & capabilities | Target customer | Notes |
|---|---|---|---|
| CFT S.p.A. (including the Rossi & Catelli heritage brand) | Complete tomato-processing and soft-fruit/vegetable processing lines (extraction, concentration, aseptic processing), beverage filling and packaging | Tomato processors, fruit and vegetable processors, beverage bottlers | ATS cites strong global brand recognition in tomato processing. Expanding into fresh fruit, secondary processing and packaging. |
| Raytec Vision | Optical inspection and sorting systems for food | Food processors | Italian; part of the food platform. |
| Marco Limited | Food and packaging-line equipment (UK) | Food producers | Named in the May 2024 release as part of the packaging portfolio. |
| Paxiom (food lines) | See 5.2 | Food producers | Cross-vertical. |
Energy
| Offering | Description & capabilities | Target customer | Notes |
|---|---|---|---|
| Nuclear refurbishment and life-extension | Specialized tooling and automation for CANDU reactor refurbishment, including fuel-handling, inspection and specialized test systems for high-risk environments | Canadian nuclear utilities and international CANDU operators | Long track record. Q4 FY2026 energy revenue up 101.5%. |
| SMR and new-build engineering | Front-end engineering, design and prototype equipment for small modular reactors and conventional new builds; automation for modular fabrication and assembly | Reactor vendors, utilities | Management estimates ATS's addressable share at a low-single-digit % of total reactor-program capex, depending on application (Q1 FY2027 release). |
| Nuclear fuel fabrication automation | Automation for fuel fabrication facilities ahead of reactor deployment | Fuel fabricators | Called out in Q1 FY2027 as a complementary opportunity. |
| Grid battery storage | Assembly automation for stationary storage | Energy-storage manufacturers | Named in the FY2026 outlook. |
Cross-portfolio digital, process automation and services
| Offering | Description | Notes |
|---|---|---|
| Process Automation Solutions (PA) | Industrial automation, MES/MOM, process control, digitalization and OT/IT integration across pharma, food and chemicals | Platform augmented by IPCOS (Belgium), IT.ACA (Italy), Zi-Argus (Australia/Thailand) and Triad Unlimited. |
| Illuminate manufacturing intelligence (ATS software) | Data-collection and production-analytics software for ATS-built and third-party lines | Part of the "data-enabled automation" strategy. The Q1 FY2027 software-asset impairment signals re-scoping of smaller software units. |
| Lifecycle services | Spares, retrofits, upgrades, relocation, field service and performance improvement | Services incl. spares revenue C$1,009.3M in FY2026; now embedded in operating units (services reorganization). |
Financial Narrative
Sources: FY2022 release (May 2022); FY2023 release (18 May 2023); FY2024 release (16 May 2024); FY2026 release (28 May 2026, with FY2025 comparatives). FY2022 detail beyond revenue, net income and EPS was not available in the documents reviewed.
Income statement
FY2022 basic EPS is from roic.ai and is consistent with net income of C$121.4M on about 92M shares. FY2022 revenue of C$2,182.7M is the comparative shown in ATS's FY2023 filings.
Margins (%)
Revenue CAGR: FY2022–FY2026 is 8.0% a year (calculated, IFRS). FY2023–FY2026 is 4.9% a year. Organic growth was 10.7% in FY2024, 6.0% in FY2026 and -6.4% in Q1 FY2027.
Quarterly run-rate
Q2 and Q3 FY2026 revenue and Q2 net income are calculated from disclosed half-year and full-year totals. Q3 net income of C$29.94M is per the RTTNews report of the 4 February 2026 release.
Balance sheet
FY2022 cash is the FY2023 opening balance. At Q1 FY2027 (28 June 2026): cash C$198.9M, long-term debt C$1,234.5M, net debt C$1,192.0M, equity C$1,802.8M, non-cash working capital 14.3%, and assets held for sale C$61.4M.
Cash flow
Q1 FY2027 operating cash flow was -C$10.3M and free cash flow -C$25.9M, against C$155.8M and C$139.5M in Q1 FY2026. Management's FY2027 capex plus intangibles guidance is C$70M–C$90M.
Key ratios
How these were calculated:
-
ROIC = adjusted EFO × (1 − about 24% adjusted tax rate) ÷ (year-end equity + net debt).
-
FY2025 net debt/EBITDA is pro forma for acquisitions, per the company.
-
The cash conversion cycle excludes contract assets and contract liabilities, which are material for a percentage-of-completion business. The company's own non-cash-working-capital ratio is the better liquidity indicator.
Commentary on trends, inflections and drivers
Revenue. ATS crossed C$3B in FY2024 on transportation/EV programs and acquisitions (Avidity, IT.ACA). FY2025 IFRS revenue fell 16.5% to C$2,533M. Of that decline, C$146.9M reflects the one-time EV settlement. Adjusted revenue fell 11.6% to C$2,680M as EV collapsed, partly offset by GLP-1 life-sciences programs and the Paxiom acquisition.
FY2026 recovered to C$2,973M (+10.8% adjusted; 6.0% organic, 2.9% FX, 1.6% acquisitions). That recovery was driven by life sciences backlog conversion, consumer/warehouse packaging, food and beverage, and nuclear. FY2027 has started with an organic decline: Q1 was -6.4%, and Q2 is guided to C$660M–C$700M, down about 7% year over year at the midpoint.
Margins. The adjusted EFO margin compressed from 13.3% in FY2023 to about 10.5% in FY2025–FY2026. The adjusted EBITDA margin moved from about 15.5% to about 13.9%. The causes were:
-
loss of high-absorption EV volume against a fixed footprint built for a C$3B+ EV-inclusive business;
-
SG&A inflation, from C$445M (17.3% of revenue) in FY2023 to C$620M (20.9%) in FY2026, reflecting acquisitions, ERP/controls remediation and public-company costs;
-
mix effects as products and services grew.
Gross margin on adjusted revenue excluding adjustment items improved sequentially and year over year in Q1 FY2027, management says. However, operating deleverage pushed the Q1 FY2027 adjusted EFO margin down to 9.8%. The stated FY2027 goal is a 50–75 basis-point improvement in adjusted EFO margin, which looks challenging given Q1. The 15% long-term target implies roughly 450 basis points of expansion, half of which the new Fixed Cost Transformation Program is meant to deliver.
Earnings quality. The gap between IFRS and adjusted earnings is large and persistent. Adjusted net income was C$165.5M in FY2026 against IFRS net income of C$71.7M. The recurring adjustments are acquisition amortization (C$58.1M), restructuring (C$23.1M), and transportation and services reorganization (C$38.1M). Investors should treat restructuring as quasi-recurring: it has been C$22.8M–C$27.5M a year for four consecutive years, and Q1 FY2027 added another C$22.2M of reorganization-type items.
Cash flow and working capital. This is the most important inflection. FY2024 and FY2025 free cash flow was negative (-C$67.6M and -C$52.3M) as EV milestone billing lagged and contract assets swelled to C$704.7M at FY2024. In FY2026, working capital released C$246.6M, the non-cash working capital ratio fell from 22.4% to 12.1%, and free cash flow reached a record C$371.7M (125% of adjusted net income after excluding the release).
Q1 FY2027 reversed part of this. Operating cash flow was -C$10.3M and the working-capital ratio rose to 14.3%. That is still within the long-term goal of below 15%.
Leverage. Net debt peaked at C$1,474.5M (3.9x pro forma adjusted EBITDA) at FY2025 after the Paxiom acquisition and EV working-capital build. FY2026 debt repayment (C$331M) brought it to 2.8x. The ratio is now drifting up again (2.9x at Q1 FY2027) as trailing EBITDA declines. Management targets 2.0–3.0x throughout FY2027. Interest burden is material: net finance costs of C$99.6M consumed 32% of adjusted EFO in FY2026.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Markets
| Market | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Life Sciences revenue (CAD Mn) | 1,209.9 | 1,268.6 | 1,471.8 | 1,522.0 |
Transportation revenue (CAD Mn) | 578.2 | 933.3 | 331.8 | 169.7 |
Food & Beverage revenue (CAD Mn) | 371.3 | 435.0 | 416.9 | 498.8 |
Consumer Products revenue (CAD Mn) | 305.1 | 287.2 | 335.7 | 553.0 |
Energy revenue (CAD Mn) | 112.9 | 108.8 | 124.0 | 226.6 |
Total revenue (CAD Mn) | 2,577.4 | 3,032.9 | 2,680.2 | 2,970.1 |
Markets (FY2024–FY2026)
| Market | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Life Sciences YoY growth (%) | 4.9 | 16.0 | 3.4 |
Transportation YoY growth (%) | 61.4 | -64.4 | -48.9 |
Food & Beverage YoY growth (%) | 17.2 | -4.2 | 19.6 |
Consumer Products YoY growth (%) | -5.9 | 16.9 | 64.7 |
Energy YoY growth (%) | -3.6 | 14.0 | 82.7 |
Total YoY growth (%) | 17.7 | -11.6 | 10.8 |
Markets — Life Sciences share
| Market | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Life Sciences share (%) | 46.9 | 41.8 | 54.9 | 51.2 |
Transportation share (%) | 22.4 | 30.8 | 12.4 | 5.7 |
Food & Beverage share (%) | 14.4 | 14.3 | 15.6 | 16.8 |
Consumer Products share (%) | 11.8 | 9.5 | 12.5 | 18.6 |
Energy share (%) | 4.4 | 3.6 | 4.6 | 7.6 |
Markets (Quarterly)
| Market (new basis) | Q1 FY2026 | Q1 FY2027 | YoY % |
|---|---|---|---|
Life Sciences | 378.8 | 345.9 | -8.7 |
Industrial & Consumer | 184.0 | 175.6 | -4.6 |
Food & Beverage | 138.5 | 117.0 | -15.5 |
Energy | 35.4 | 59.8 | 68.9 |
Total adjusted revenue | 736.7 | 698.3 | -5.2 |
Markets — Life Sciences backlog
| Market | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Life Sciences backlog (CAD Mn) | 761 | 871 | 1,199 | 1,077 |
Transportation backlog (CAD Mn) | 939 | 425 | 214 | 129 |
Food & Beverage backlog (CAD Mn) | 215 | 230 | 258 | 214 |
Consumer Products backlog (CAD Mn) | 156 | 156 | 282 | 278 |
Energy backlog (CAD Mn) | 82 | 111 | 186 | 260 |
Total backlog (CAD Mn) | 2,153 | 1,793 | 2,139 | 1,958 |
Revenue by Segment and Revenue by Segment (x)
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Order Bookings (CAD Mn) | 3,256 | 2,891 | 3,305 | 2,952 |
Book-to-bill (x, calculated) | 1.26 | 0.95 | 1.23 | 0.99 |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue IFRS (CAD Mn) | 2,182.7 | 2,577.4 | 3,032.9 | 2,533.3 | 2,972.9 |
Adjusted revenue (CAD Mn) | 2,182.7 | 2,577.4 | 3,032.9 | 2,680.2 | 2,970.1 |
Cost of revenues (CAD Mn) | — | 1,851.6 | 2,177.4 | 1,886.6 | 2,122.1 |
Gross profit (CAD Mn, calculated) | — | 725.8 | 855.5 | 646.7 | 850.9 |
SG&A (CAD Mn) | — | 445.2 | 503.5 | 604.2 | 620.3 |
Restructuring costs (CAD Mn) | — | 27.5 | 22.8 | 24.0 | 23.1 |
Earnings from operations (CAD Mn) | — | 222.5 | 315.4 | 9.3 | 198.8 |
Adjusted earnings from operations (CAD Mn) | — | 343.4 | 397.5 | 282.6 | 314.4 |
Depreciation & amortization (CAD Mn) | — | 125.5 | 141.2 | 152.7 | 163.9 |
EBITDA (CAD Mn) | — | 348.0 | 456.6 | 162.0 | 362.7 |
Adjusted EBITDA (CAD Mn) | — | 401.2 | 470.6 | 368.9 | 413.0 |
Net finance costs (CAD Mn) | — | 62.7 | 68.7 | 92.2 | 99.6 |
Pre-tax income (CAD Mn) | — | 159.8 | 246.7 | -82.9 | 99.2 |
Income tax expense (CAD Mn) | — | 32.1 | 52.5 | -55.0 | 27.5 |
Net income (CAD Mn) | 121.4 | 127.7 | 194.2 | -28.0 | 71.7 |
Basic EPS (CAD) | 1.32 | 1.39 | 1.98 | -0.29 | 0.73 |
Diluted EPS (CAD) | — | 1.38 | 1.97 | -0.29 | 0.73 |
Adjusted basic EPS (CAD) | — | 2.37 | 2.61 | 1.47 | 1.69 |
Dividends per share (CAD) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin IFRS (%) | — | 28.2 | 28.2 | 25.5 | 28.6 |
Operating margin EFO/revenue (%) | — | 8.6 | 10.4 | 0.4 | 6.7 |
Adjusted EFO margin (%) | — | 13.3 | 13.1 | 10.5 | 10.6 |
EBITDA margin (%) | — | 13.5 | 15.1 | 6.4 | 12.2 |
Adjusted EBITDA margin (%) | — | 15.6 | 15.5 | 13.8 | 13.9 |
Net margin (%) | 5.6 | 5.0 | 6.4 | -1.1 | 2.4 |
Income Statement and Per-Share Data (Quarterly)
| Metric | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Q4 FY2026 | Q1 FY2027 |
|---|---|---|---|---|---|
Revenue IFRS (CAD Mn) | 736.7 | 728.5 | 760.6 | 747.1 | 693.7 |
Net income (CAD Mn) | 24.3 | 33.7 | 29.9 | -16.2 | -0.3 |
Adjusted EBITDA (CAD Mn) | 101.5 | — | — | 102.5 | 92.9 |
Adjusted basic EPS (CAD) | 0.41 | — | — | 0.36 | 0.35 |
Order Bookings (CAD Mn) | 693 | 734 | 821 | 704 | 656 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (CAD Mn) | — | 3,543.8 | 4,088.8 | 4,621.9 | 4,340.0 |
Cash & equivalents (CAD Mn) | 135.3 | 159.9 | 170.2 | 225.9 | 285.0 |
Bank indebtedness (CAD Mn) | — | 5.8 | 4.1 | 27.3 | 6.7 |
Short-term debt incl. current leases (CAD Mn) | — | 24.1 | 27.8 | 32.9 | 35.4 |
Long-term debt (CAD Mn) | — | 1,155.7 | 1,171.8 | 1,543.5 | 1,274.6 |
Long-term lease liabilities (CAD Mn) | — | 73.3 | 83.8 | 96.7 | 119.5 |
Total debt incl. leases (CAD Mn, calculated) | — | 1,258.9 | 1,287.5 | 1,700.4 | 1,436.2 |
Net debt (CAD Mn) | — | 1,099.0 | 1,117.3 | 1,474.5 | 1,151.2 |
Total equity (CAD Mn) | — | 1,130.6 | 1,683.9 | 1,709.4 | 1,779.5 |
Goodwill (CAD Mn) | — | 1,118.3 | 1,228.6 | 1,394.6 | 1,399.3 |
Intangible assets (CAD Mn) | — | 593.2 | 679.5 | 758.5 | 704.2 |
Working capital: current assets less current liabilities (CAD Mn, calculated) | — | 408.4 | 724.5 | 779.9 | 668.2 |
Non-cash working capital (CAD Mn) | — | 278.5 | 586.1 | 614.2 | 365.1 |
Non-cash working capital % of revenue | — | 10.1 | 19.0 | 22.4 | 12.1 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (CAD Mn) | — | 127.8 | 20.8 | 25.8 | 448.4 |
Capex PP&E (CAD Mn) | — | 56.1 | 58.8 | 34.0 | 33.6 |
Intangible asset additions (CAD Mn) | — | 24.2 | 29.6 | 44.1 | 43.1 |
Free cash flow (CAD Mn) | — | 47.5 | -67.6 | -52.3 | 371.7 |
Business acquisitions net of cash (CAD Mn) | — | 51.7 | 276.5 | 179.4 | 0 |
Dividends paid (CAD Mn) | 0 | 0 | 0 | 0 | 0 |
Share repurchases (CAD Mn) | — | 21.1 | 0.0 | 45.0 | 10.0 |
Shares acquired for RSU trust (CAD Mn) | — | 12.4 | 23.8 | 14.7 | 9.6 |
Net equity issued, U.S. IPO (CAD Mn) | — | 0 | 362.1 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
ROE on average equity (%) | — | 13.8 | -1.7 | 4.1 |
ROA on average assets (%) | — | 5.1 | -0.6 | 1.6 |
ROIC, adjusted after-tax (%) | 11.7 | 10.8 | 6.7 | 8.3 |
Current ratio (x) | 1.39 | 1.70 | 1.69 | 1.64 |
Debt-to-equity, company definition (x) | 1.18 | 0.79 | 1.10 | 0.89 |
Net debt / adjusted EBITDA (x) | 2.7 | 2.4 | 3.9 | 2.8 |
Interest coverage EFO / net finance (x) | 3.5 | 4.6 | 0.1 | 2.0 |
Interest coverage adj. EFO / net finance (x) | 5.5 | 5.8 | 3.1 | 3.2 |
Asset turnover (x) | — | 0.79 | 0.58 | 0.66 |
DSO, receivables only (days) | 56.6 | 56.7 | 103.7 | 64.3 |
DIO (days) | 50.6 | 49.6 | 61.9 | 50.8 |
DPO, payables and accruals (days) | 127.7 | 101.3 | 128.7 | 107.1 |
Cash conversion cycle (days) | -20.5 | 5.0 | 36.9 | 8.0 |
Revenue by Region
| Region | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
North America revenue (CAD Mn) | 1,525.5 | 1,766.5 | 1,432.0 | 1,558.6 |
Europe revenue (CAD Mn) | 811.7 | 990.1 | 938.6 | 1,020.5 |
Asia/Other revenue (CAD Mn) | 240.2 | 276.3 | 309.6 | 391.0 |
Total revenue (CAD Mn) | 2,577.4 | 3,032.9 | 2,680.2 | 2,970.1 |
Region Margins & Growth (%)
| Region | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
North America YoY growth (%) | 15.8 | -18.9 | 8.8 |
Europe YoY growth (%) | 22.0 | -5.2 | 8.7 |
Asia/Other YoY growth (%) | 15.0 | 12.1 | 26.3 |
Revenue by Region (%)
| Region | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
North America share (%) | 59.2 | 58.2 | 53.4 | 52.5 |
Europe share (%) | 31.5 | 32.6 | 35.0 | 34.4 |
Asia/Other share (%) | 9.3 | 9.1 | 11.6 | 13.2 |
Valuation Snapshot
| Metric | Value | Source / note |
|---|---|---|
NYSE price, early October 2026 | About US$17.7–18.3 (52-week low US$17.72 on 7 October 2026) | MarketBeat |
TSX price, 2 September 2026 | C$26.29 | Stockwatch |
TSX 52-week high | C$49.48 | WealthAwesome (mid-2026) |
NYSE 52-week high | About US$35.82 | AInvest (August 2026) |
1-year performance | About -45% to -50% (TSX, calculated from the 52-week high and early-October level). Fintel reported -28.1% as of 21 August 2026. | Approximate |
Key event moves | -11.5% intraday on 28 May 2026 (Q4 FY2026); -26.55% on 6 August 2026 (Q1 FY2027) | Stock Track; Levi & Korsinsky notice |
Beta | 1.18 | MarketBeat |
Valuation Multiples
| Multiple | ATS | Basis |
|---|---|---|
Market cap (CAD Mn) | about 2,395 | Calculated |
Enterprise value (CAD Mn) | about 3,587 | Market cap plus net debt (including leases) |
P/E (IFRS, TTM) | about 51x | TTM basic EPS C$0.48 (MarketBeat shows 52.4x) |
P/E (adjusted, TTM) | about 15x | TTM adjusted EPS C$1.63 |
EV / adjusted EBITDA (TTM) | about 8.9x | TTM pro forma adjusted EBITDA C$404.3M |
EV / sales (TTM) | about 1.2x | TTM adjusted revenue about C$2,932M |
P/B | about 1.3x | Book value per share about C$18.4 |
FCF yield (FY2026 FCF) | about 15% | C$371.7M / market cap; flattered by working-capital release |
Capital Markets
| Item | Detail |
|---|---|
Coverage | About 17 analysts (Simply Wall St); 6–7 active in recent months |
Rating mix (MarketBeat, October 2026) | 3 Buy, 2 Hold, 2 Sell; consensus "Hold" |
Rating mix (TipRanks, 3-month) | 4 Buy, 2 Hold; "Moderate Buy" |
Recent target actions | RBC C$50 → C$41 (10 August 2026); Stifel C$52 → C$44, Buy (7 August 2026); TD Securities Buy → Hold (10 August 2026); Scotiabank C$48 → C$51, Sector Outperform (28 April 2026, before the decline) |
Consensus target | Sources conflict. MarketBeat shows US$42.50 (likely stale, pre-August). TipRanks NYSE shows US$32.95 (about 23% upside from US$26.88 when published). |
Consensus EPS | MarketBeat: about US$1.12 for the current fiscal year (basis unclear) |
Moody's / S&P / Fitch ratings | ATS has historically carried sub-investment-grade (high-yield) corporate ratings; current ratings and outlooks should be confirmed with the agencies. |
Long-term debt (Q1 FY2027) | C$1,234.5M, plus C$155.3M of lease liabilities |
Composition | Senior unsecured notes plus a senior secured revolving credit facility. |
FY2026 debt activity | C$331.4M repaid; C$85.0M drawn |
Q1 FY2027 debt activity | C$50.1M repaid |
Cash interest paid | C$97.5M (FY2026) |
Maturity profile | Not publicly disclosed in the documents reviewed (see the 40-F liquidity note). Current portion of long-term debt is only C$0.2M, so there is no near-term maturity wall within 12 months. |
Dividends & Capital Returns
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Dividends per share (CAD) | 0 | 0 | 0 | 0 | 0 |
Share repurchases (CAD Mn) | — | 21.1 | 0.0 | 45.0 | 10.0 |
Analyst Conclusions
Management guidance (as of 6 August 2026)
-
Q2 FY2027 revenue of C$660M–C$700M, about 7% lower year over year at the midpoint.
-
FY2027 "modest" organic growth, now explicitly dependent on stronger H2 bookings and faster execution. This is net of about C$50M of exited transportation revenue.
-
FY2027 adjusted EFO margin up 50–75 basis points (from 10.6%). Q1 delivered 9.8%, so H2 must improve materially.
-
Leverage of 2.0–3.0x throughout FY2027; capex plus intangibles of C$70M–C$90M.
-
Fixed Cost Transformation Program over about 18 months: Phase 1 about C$20M a year in Europe, about 30% of the total opportunity. Further phases and program costs to be disclosed.
-
Long-term 15% adjusted EFO margin target unchanged.
Consensus growth expectations
Directionally, the sell-side cut targets by 15–20% after Q1 FY2027 (RBC, Stifel) and moved toward Hold. MarketBeat's aggregated forecast implies current-year EPS of about US$1.12. The Q2 guidance midpoint of about C$680M sits below the roughly US$510M (about C$700M) consensus that preceded it.
Bull case
-
Cost-out plus normalizing revenue drive outsized EPS leverage. If the full program delivers about C$65–70M a year (implied by Phase 1 being about 30% of a roughly C$20M-per-tranche opportunity) on a revenue base of about C$2.9–3.0B, adjusted EFO margin could rise by roughly 230 bps from cost alone. That would take it toward about 13% before any volume recovery. At about 15x adjusted earnings the market is not paying for this.
-
Structural growth vectors are real and accelerating. Energy revenue doubled in FY2026 and energy backlog rose 40%. Radiopharma bookings recur. Non-GLP-1 life-sciences book-to-bill is about 1.1x. Services are growing double digits (+11.4% in Q1 FY2027). About 80% of backlog is in regulated markets with high switching costs.
-
Cash generation and valuation give downside support. FY2026 free cash flow of C$371.7M equals about 15% of today's market cap. Leverage is within range, the NCIB is active (8.2M-share authorization) and EV/EBITDA is about 9x. Even normalized FCF of C$200–250M implies a high-single to low-double-digit FCF yield.
Bear case
-
The growth reset may be cyclical and structural, not timing. GLP-1 capacity has been built, EV is gone, tomato processing is rolling over, and backlog is down 8.7% year over year to C$1,889M. Q1 missed the bottom of guidance and Q2 is guided lower still. "Modest growth" for FY2027 looks increasingly unlikely.
-
Execution and governance credibility is impaired. The company has had material weaknesses for two consecutive years, an interim CFO since February 2026, four consecutive years of "non-recurring" restructuring (C$23–28M a year), restructuring slippage in Q1 FY2027, project disputes (EV settlement, Andersen) and a securities investigation. Adjusted metrics may persistently overstate economic earnings.
-
Leverage may tighten as EBITDA falls. Net debt/EBITDA has risen from 2.8x to 2.9x and the trailing EBITDA trend is down. Restructuring cash costs come ahead of savings, and interest consumes about one-third of adjusted EFO. A further revenue miss could push leverage above 3x, constraining M&A and buybacks just as management wants to deploy capital.
Key catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Timing | What to watch |
|---|---|---|
| Q2 FY2027 results | Early November 2026 (expected) | Revenue versus C$660M–C$700M; bookings rebound (large-award conversion); adjusted EFO margin; operating cash flow |
| Fixed Cost Transformation Program, Phase 2+ disclosure | FY2027 | Total savings quantification, program cost, site closures beyond Europe |
| Permanent CFO appointment | Pending | Calibre and timing; stabilization of the finance function |
| Material weakness remediation | By FY2027 year-end (31 March 2027) | Successful ERP upgrade; clean ICFR opinion in the FY2027 40-F |
| Sale of held-for-sale facilities | FY2027 | Proceeds versus the C$61.4M carrying value; funding of restructuring |
| Nuclear and SMR awards | Rolling | Refurbishment and SMR fuel-fabrication orders; energy bookings recovery after Q1 FY2027's decline |
| GLP-1 versus non-GLP-1 life-sciences mix | Quarterly | Stabilization of life-sciences revenue; radiopharma and pharma bookings |
| USMCA review / U.S. tariffs | Ongoing | Any change in Section 232/301 tariffs that affects the roughly 20% of revenue crossing the border |
| Securities investigation | Ongoing | Whether a class action is filed |
| NCIB execution and M&A | Ongoing | Pace of buybacks versus leverage; resumption of bolt-on M&A |
| FY2027 full-year results and FY2028 outlook | May 2027 | Delivery of the margin uplift; updated long-term targets |
Analyst verdict
ATS Corporation is a fundamentally sound franchise going through a poorly timed transition. On the positive side, it has assembled real competitive assets: a C$1.5B life-sciences automation business with validated-process know-how, a services and spares stream above C$1B, proprietary platforms (SuperTrak, Comecer, SP, CFT, IWK), and credible positions in the two most interesting long-cycle capex themes of the decade, nuclear power and radiopharmaceuticals. FY2026 showed what the business can do when working capital behaves: C$372M of free cash flow and leverage cut from 3.9x to 2.8x.
The problem is that three things are happening at once. Revenue is resetting as EV disappears, GLP-1 capacity normalizes and food processing cools. The cost base was sized for a C$3B+ business with EV programs. Leadership and control credibility has been dented by CEO and CFO turnover, two years of material weaknesses, and a Q1 FY2027 guidance miss followed by slipping restructuring. The roughly 64% fall from the 52-week high reflects all three.
At about 9x EV/EBITDA, about 15x adjusted earnings and about 1.3x book, the valuation already discounts a prolonged margin plateau near 10%. Doug Wright's Fixed Cost Transformation Program is the correct prescription. His Honeywell and Indicor background suggests disciplined portfolio and footprint management, and Phase 1 alone (about C$20M a year) is meaningful against FY2026 adjusted net income of C$165.5M.
However, the investment case now depends on execution evidence that does not yet exist: bookings recovering above C$700M a quarter, a permanent CFO, clean controls and quantified Phase 2 savings. Our stance is Neutral with a positive bias. ATS is an attractive self-help and recovery candidate for patient capital, but sizing should wait for one or two quarters of proof that revenue has bottomed and that cost savings are reaching the P&L rather than being absorbed by recurring "one-time" charges.
End of dossier. All figures are in C$ and on an IFRS basis unless noted. Adjusted measures are ATS non-IFRS measures as defined in its filings. Third-party and market data are point-in-time estimates and should be refreshed before investment use.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles / background | Age |
|---|---|---|---|---|
Doug Wright | Chief Executive Officer and Director | Since 14 January 2026 | CEO of Indicor (diversified industrial solutions, from April 2023); President & CEO, Building Technologies at Honeywell International; President & CEO of Source Photonics; leadership roles at United Technologies (now RTX) and Ingersoll Rand | 54 (Simply Wall St) |
Anne Cybulski | Interim Chief Financial Officer; VP and Corporate Controller | Interim CFO since 15 February 2026 (also interim CFO from August 2025 to January 2026); joined ATS 2009; Corporate Controller since 2022 | Progressive ATS finance roles | — |
Sarah Moore | Group Executive, Life Sciences | — | Represented ATS at the Jefferies Industrials Conference, September 2026 | — |
Jeff Adamson | Senior officer (insider filer) | — | Bought 953 shares at C$39.12 on 7 July 2026 | — |
Giuseppe (Joe) Tassone | Senior officer (insider filer) | — | Sold 4,842 shares at C$41.55 on 2 June 2026 | — |
David Ocampo | Head of Investor Relations | — | Succeeded David Galison | — |
Matthew Robinson | Director, Corporate Affairs & Communications | — | — | — |
“—” = not publicly disclosed.
Board & Management Changes
| Date | Change | Context |
|---|---|---|
7 July 2025 | CEO Andrew Hider to step down by end-August 2025 | Left to lead Baxter International after about 8 years as ATS CEO (from 2017). CFO Ryan McLeod named interim CEO; Anne Cybulski interim CFO. |
FY2026 Q2 | C$7.3M stock-based compensation forfeiture | Reversal of previously recorded expense on the former CEO's departure. |
16 December 2025 | Doug Wright appointed CEO, effective on or before 14 January 2026 | Comprehensive board-led search. Chair Michael Martino cited Wright's operating discipline and fit with the ABM. CEO inducement costs: C$1.3M in Q4 FY2026 and C$1.4M in Q1 FY2027. |
19 January 2026 | CFO Ryan McLeod resigns, effective 15 February 2026 | Joined CAE Inc. as CFO effective 23 February 2026. McLeod had about 18–20 years at ATS, including CFO from 2020, and led the U.S. IPO and 18 acquisitions. Cybulski named interim CFO; permanent search under way. As of October 2026 no permanent appointment was found in this research. |
Board of Directors
| Name | Role | Notes |
|---|---|---|
Michael Martino | Chair of the Board | Quoted as Chair in the December 2025 and January 2026 releases |
Doug Wright | Director (CEO) | Appointed December 2025 / January 2026 |
Major Shareholders
| Holder | Shares | Value / note | Source |
|---|---|---|---|
Royal Bank of Canada (RBC Global Asset Management) | 7,761,838 | About US$218.9M; roughly 7.9% of outstanding | MarketBeat (13F-based), October 2026 |
Undisclosed holder (named in the MarketBeat summary but not in excerpt) | 7,168,112 | About US$202.1M; roughly 7.3% | MarketBeat, October 2026 |
Janus Henderson Group | 2,297,214 | Added 1,435,375 shares | MarketBeat, October 2026 |
TD Asset Management | 1,193,208 | About US$32.9M | MarketBeat, September 2026 |
Other top-10 holders | — | Not publicly disclosed in the documents reviewed; full register via SEDI/13F/early-warning filings | — |
Competitive Landscape
Competitors by Segment
| Vertical | Named competitors | Positioning vs ATS |
|---|---|---|
Life Sciences: device assembly and pharma equipment | Syntegon (private), Körber Pharma (private), IMA Group (private), Optima Packaging (private), Groninger (private), Bausch+Ströbel (private), Teamtechnik (Dürr Group), Jabil Healthcare (contract manufacturer) | ATS is among the leading independent auto-injector and wearable assembly specialists. European family-owned peers are strong in fill-finish where ATS is weaker. |
Radiopharmaceuticals | Tema Sinergie (private), Getinge (isolators), Comecer is ATS's own brand | ATS holds a top-tier position via Comecer. |
Lab equipment | Thermo Fisher Scientific, Azbil Telstar (lyophilizers), GEA (pharma freeze-dryers), IMA Life | SP Scientific is a niche leader; it competes with much larger scientific-equipment groups. |
Consumer / packaging / warehouse | Coesia (private), Syntegon, Krones (packaging), Pro Mach (private), Duravant (private), regional integrators | ATS is a mid-scale player that differentiates through SuperTrak and high-speed assembly. |
Food & Beverage processing | GEA Group, JBT Marel, Krones, Tetra Pak (Tetra Laval), Bertuzzi (private) | CFT is strong in tomato processing; it faces larger peers in broader food processing. |
Energy / nuclear | Specialized nuclear engineering firms; Canadian nuclear supply chain (e.g., AtkinsRéalis, BWXT-related suppliers, Kinectrics) | ATS is a niche automation and tooling specialist rather than a prime contractor. |
Transportation / EV (de-emphasized) | Comau, Dürr (assembly), ThyssenKrupp Automation Engineering, KUKA Systems, Manz, regional integrators | ATS is exiting dilutive work in this market. |
Industrial automation and digital | Rockwell Automation (including its systems-integration and MES businesses), Siemens, Emerson, Accenture Industry X, regional integrators | PA, IPCOS and Illuminate compete in MES and process-control integration. |
Peer Comparison FY2026
| Metric | ATS (FY2026, C$) | Rockwell Automation (FY2024, US$) | Dürr AG (FY2024, €) | GEA Group (FY2024, €) |
|---|---|---|---|---|
Revenue (billions, local currency) | 2.97 | about 8.3 | about 4.7 | about 5.4 |
Organic / reported growth | +6.0% organic | about -9% reported | about +1% reported | about -0.5% reported |
Margin reference | Adjusted EBITDA 13.9% | Segment operating margin about 20% | EBIT margin (pre-extraordinary) about 5–6% | EBITDA (pre-restructuring) about 15–16% |
R&D intensity | Not disclosed (intangible additions about 1.5%) | about 7% | about 3–4% | about 3% |
Listing | TSX/NYSE | NYSE | XETRA | XETRA |



